KRAS mutation profile in colorectal cancer patients in Brazil: A cohort of 989 individuals

Zalis, Mariano; Vieira, F. M.; Zalcberg-Renault, Ilana; Bonamino, Martín; Ferreira, Carmen Verı́ssima; Oliveira, Sátiro Nakamura De

doi:10.1200/jco.2009.27.15_suppl.e15017

Cited by 11 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutant K-RAS was found in 39.5% of rectum carcinomas, in which a 12 Val mutation was observed (37.5%). Similarly to previous findings, a K-RAS mutation was observed in proximal tumors (p=0.023) and in tumors with distant metastasis (p=0.020) (15,16). Conversely, one study did not find any statistically significant correlation between proximal tumor location, higher tumor grade, and absence of peritumoral lymphocytic inflammation and mutant K-RAS (17).…”

Section: Discussionsupporting

confidence: 87%

K-RAS Mutation Profile in Puerto Rican Patients with Colorectal Cancer: Trends from April 2009 to January 2011

2013

View full text Add to dashboard Cite

The frequency of K-RAS mutations ranges between 30% and 48% among the Caucasian, Asian, and European populations and these mutations are predictors of response to EGFR therapies. We sought to determine the expression of K-RAS gene mutations among colorectal cancer patients in PuertoRico. A retrospective study was conducted to determine the expression of mutant K-RAS among colorectal cancer patients in Puerto Rico between April 2009 and January 2011. The mutant expression of K-RAS was found in 39% (n=195) of the Puerto Rican population, and was more common in the age group of 51–69 years (53.8%) and in males (55.4%, p>0.05). Moreover, mutant K-RAS was more commonly found in tumors of the proximal area (43.8%; p=0.03), with distant metastasis (43.3%, p=0.018), with a mucinous histotype (31.7% p>0.05), and in ulcerated tumors (38.8%, p>0.05). K-RAS mutations were observed on codon 12 (87.7%) and codon 13 (12.3%). The most frequent mutation on codon 12 was 12 ASP (39.5%), followed by 12 VAL (25.4%) that is associated with a significant decrease in overall cancer survival. The mutant expression of K-RAS in cases of rectum carcinoma was 39.5%, where the most common mutation was 12 VAL (37.5%). The frequency of K-RAS mutations in the Puerto Rican population here studied was 39% and mutant K-RAS was associated with advanced colorectal cancer stage, mucinous histotype, and ulcerated tumors.

show abstract

Section: Discussionsupporting

confidence: 87%

K-RAS Mutation Profile in Puerto Rican Patients with Colorectal Cancer: Trends from April 2009 to January 2011

2013

View full text Add to dashboard Cite

show abstract

“…The findings of these investigations corroborate our study's outcome that approximately thirty-six percent of the patients have KRAS gene mutation. This prevalence rate was similar to data reported from the US (35.7% [104] and 31% [105]), China (32%) [106], Japan (33.5%) [107], Taiwan (33.5%) [37], Russia (35.9%) [108], France (33.8) [109], the United Kingdom (36.9%) [110], and Brazil (36%) [111], although KRAS prevalence was reported to slightly differ from some published data from Germany (41%) [112], Italy (62.2%, 43%, and 43%) [113][114][115], Turkey (44%) [116], Morocco (24%) [117], and Egypt (11% and18.4%) [118,119]. These latter differences could be associated with various factors such as race, lifestyle, period, and means of sample collection and geographical locations.…”

Section: Discussionsupporting

confidence: 89%

A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

Afolabi

Salleh

Zunita

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Globally, colorectal carcinoma (CRC) is the third most common cancer and the third major cause of cancer-related death in both sexes. KRAS and BRAF mutations are almost mutually exclusively involved in the pathogenesis of CRC. Both are major culprits in treatment failure and poor prognosis for CRC. Method. A systematic review and meta-analysis of various research was done following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. This trial is registered with PROSPERO CRD42021256452. The initial search included 646 articles; after the removal of noneligible studies, a total of 88 studies was finally selected. Data analysis was carried out using OpenMeta Analyst and Comprehensive Meta-Analysis 3.0 (CMA 3.0) software to investigate the prevalence of KRAS and BRAF mutations among patients with CRC in Asia. Results. The meta-analysis comprises of 25,525 sample sizes from Asia with most being male 15,743/25525 (61.7%). Overall prevalence of KRAS mutations was (59/88) 36.3% (95% CI: 34.5-38.2) with I 2 = 85.54 % ( P value < 0.001). In 43/59 studies, frequency of KRAS mutations was majorly in codon 12 (76.6% (95% CI: 74.2–78.0)) and less in codon 13 (21.0% (95% CI: 19.1-23.0)). Overall prevalence of BRAF mutations was 5.6% (95% CI: 3.9-8.0) with I 2 = 94.00 % ( P value < 0.001). When stratified according to location, a higher prevalence was observed in Indonesia (71.8%) while Pakistan has the lowest (13.5%). Conclusion. Total prevalence of KRAS and BRAF mutations in CRC was 36.6% and 5.6%, respectively, and the results conformed with several published studies on KRAS and BRAF mutations.

show abstract

“… 93 Consistent results were reported in a large-scale study in Brazil, with KRAS mutations in codons 12 and 13 found in 87% and 13% of patients, respectively. 68 However, a study on the Greek population reported a lower frequency of KRAS mutations in codon 12, at 29.3%. 94 Various genetic and environmental factors contribute to the frequency and distribution of KRAS mutations, leading to variations across different ethnic populations.…”

Section: Discussionmentioning

confidence: 98%

“…Although some studies suggest a higher likelihood of mutant KRAS in women, 66 , 67 others indicate the opposite trend. 43 , 68 …”

Section: Discussionmentioning

confidence: 99%

“… 113 - 117 The incidence of BRAF mutations varies significantly across populations, with Taiwan recording the lowest at 1% and the Netherlands and the United States reporting the highest at 19.8% and 21.8%, respectively. 52 - 56 , 62 , 68 , 71 - 109 , 111 - 116 Interestingly, Asian populations generally exhibit lower incidences, with rates ranging from 3.8% to 7% in China and 4.7% to 6.7% in Japan. 118 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Benmokhtar,

Laraqui,

Hilali

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: This review article aims to investigate the prevalence and spectrum of rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations, and their connection with geographical location, clinicopathological features, and other relevant factors in colorectal cancer (CRC) patients in the Middle East. Methods: A systematic literature review, employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, was conducted to investigate the association between the frequency of relevant mutations and the descriptive clinicopathological characteristics of CRC patients. Multiple electronic databases, including PubMed, Science Direct, Web of Science, Scopus, and Google Scholar, were searched to analyze the relevant literature. Results: A total of 19 eligible studies comprising 2960 patients with CRC were included in this review. A comprehensive analysis of the collected literature data as well as descriptive and methodological insights is provided. Men were predominant in reviewed studies for the region, accounting for 58.6%. Overall, RAS mutation prevalence was 38.1%. Kirsten RAS Viral Oncogene Homolog (KRAS) mutations were the most common, accounting for 37.1% of cases and distributed among different exons, with the G12D mutation being the most frequent in exon 2 (23.2%) followed by G12V (13.7%), G13D (10.1%), G12C (5.1%), G12A (5.04%), and G12S (3.6%). Neuroblastoma RAS Viral Oncogene Homolog (NRAS) mutations were identified in 3.3% of tumor samples, with the most common mutation site located in exons 2, 3, and 4, and codon 61 being the most common location for the region. The total mutation frequency in the BRAF gene was 2.6%, with the V600E mutation being the most common. Conclusion: The distribution patterns of RAS and BRAF mutations among CRC patients exhibit notable variations across diverse ethnic groups. Our study sheds light on this phenomenon by demonstrating a higher prevalence of KRAS mutations in CRC patients from the Middle East, as compared with those from other regions. The identification of these mutations and geographical differences is important for personalized treatment planning and could potentially aid in the development of novel targeted therapies. The distinct distribution patterns of RAS and BRAF mutations among CRC patients across different ethnic groups, as well as the regional variability in mutation prevalence, highlight the need for further research in this area.

show abstract

KRAS mutation profile in colorectal cancer patients in Brazil: A cohort of 989 individuals

Cited by 11 publications

References 0 publications

K-RAS Mutation Profile in Puerto Rican Patients with Colorectal Cancer: Trends from April 2009 to January 2011

K-RAS Mutation Profile in Puerto Rican Patients with Colorectal Cancer: Trends from April 2009 to January 2011

A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Contact Info

Product

Resources

About